A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

🅇 This trial is currently recruiting participants in the UK

Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.

Inclusion Criteria: 1. Participant is capable of giving signed informed consent 2. Male and female healthy participant between 18 to 55 years of age (inclusive) at screening, with suitable veins for cannulation or repeated venipuncture. 3. Body-mass index between 18.5 – 29.9 kg/m2 (inclusive) with body weight ≥ 50 kg and < 95 kg at screening. 4. Participant agrees to be available for the entire duration of the study 5. All female participants must have a negative serum pregnancy test at the screening visit and on admission to the Clinical Unit (Day -1). 6. Female Participants: • A female participant is eligible to participate if she is not pregnant, not be lactating and not breastfeeding, and at least one of the following conditions applies 7. Male Participants • Male participants and their female spouse/partners who are of childbearing potential must be using 2 forms of birth control from screening until…